TrialJournal of thrombosis and thrombolysis2016

A post hoc analysis of dalteparin versus oral anticoagulant (VKA) therapy for the prevention of recurrent venous thromboembolism (rVTE) in patients with cancer and renal impairment.

Seth Woodruff et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.